KKHA-761

potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia; structure in first source

Also Known As:

1-(4-(3-(3,4-dimethoxyphenyl)-isoxazol-5-yl)butyl)-4-(2-methoxyphenyl)piperazine

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Isoxazoles: 155
      - KKHA-761: 1
  - Piperazines: 26
    - KKHA-761: 1

Experts

1.	Cha, Mi Young: 1 article (10/2005)
2.	Cho, Heeyeong: 1 article (10/2005)
3.	Choi, Kyung Il: 1 article (10/2005)
4.	Jeong, Daeyoung: 1 article (10/2005)
5.	Koh, Hun Yeong: 1 article (10/2005)
6.	Kong, Jae Yang: 1 article (10/2005)
7.	Lee, Seong Jin: 1 article (10/2005)
8.	Pae, Ae Nim: 1 article (10/2005)
9.	Park, Woo-Kyu: 1 article (10/2005)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 10/01/2005 - "KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia."
2.	Catalepsy 10/01/2005 - "KKHA-761 did not induce cataleptic response up to 20 mg/kg, but significant catalepsy was shown at lower doses of clozapine and haloperidol. "
3.	Ataxia (Dyssynergia) 10/01/2005 - "Furthermore, KKHA-761 showed a low incidence of rotarod ataxia (TD50=34.4 mg/kg, i.p.) in mice. "

Related Drugs and Biologics

1.	5-HT1A Serotonin Receptor
2.	Antipsychotic Agents (Antipsychotics)
3.	Haloperidol (Haldol)
4.	Clozapine (Clozaril)